1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,133 | 0,242 | 23.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Cantargia Q2 2026 slides: cash runway extends, MDS remissions shine | 1 | Investing.com | ||
| Mi | Cantargia Publishes Half-Year Report 2026 | 318 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 19, 2026 / Cantargia AB (publ) (STO:CANTA) today published its interim report for the second quarter and first six months of 2026."Over the next nine to twelve months... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| Mi | Cantargia AB: Cantargia publishes Half-Year Report 2026 | 139 | GlobeNewswire (Europe) | Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today published its interim report for the second quarter and first six months of 2026.
"Over the next nine to twelve months, we will lay the groundwork... ► Artikel lesen | |
| 04.08. | Cantargia to Host Q2 2026 Interim Results Conference Call | 270 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 4, 2026 / Cantargia AB (publ), "Cantargia" (STO:CANTA) will publish its interim report for January - June 2026 on Wednesday, August 19, 2026, at 07:00 a.m. CEST.Interested... ► Artikel lesen | |
| 31.07. | Cantargia Announces Changes in Number of Shares and Votes | 478 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 31, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia has changed due to the recently... ► Artikel lesen | |
| 26.06. | Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC | 371 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 26, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the publication of preclinical and clinical findings from the nadunolimab trial CANFOUR in the scientific... ► Artikel lesen | |
| 23.06. | Cantargia AB: Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital | 220 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE... ► Artikel lesen | |
| 11.06. | Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC | 288 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 11, 2026 / Cantargia AB (Publ) (STO:CANTA) today announced a KOL Call to be hosted in collaboration with H.C. Wainwright with leading subject matter experts Drs. Peter... ► Artikel lesen | |
| 10.06. | Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study | 368 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 10, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current... ► Artikel lesen | |
| 05.06. | Cantargia AB: Cantargia publishes Information Document regarding Rights Issue of Shares | 277 | GlobeNewswire (Europe) | Cantargia AB (publ) ("Cantargia" or the "Company") publishes an information document (the "Information Document") relating to the rights issue of shares of approximately SEK 124 million before deduction... ► Artikel lesen | |
| 03.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.06.2026 | 505 | Xetra Newsboard | Das Instrument 7V3 SE0006371126 CANTARGIA AB EQUITY wird ex Kapitalmassnahme gehandelt am 03.06.2026 The instrument 7V3 SE0006371126 CANTARGIA AB EQUITY is traded ex capital adjustment on 03.06.2026Das... ► Artikel lesen | |
| 28.05. | Cantargia AB to Host Webcast Covering Rights Issue, Loan Agreement, and Strategic Priorities | 390 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 28, 2026 / Cantargia (STO:CANTA) - With reference to the Company's press release on May 28, 2026, regarding the decision to conduct a rights issue in combination with... ► Artikel lesen | |
| 28.05. | Cantargia AB: Cantargia AB carries out a rights issue of SEK 124 million and enters into a loan agreement of up to SEK 75 million | 562 | GlobeNewswire (Europe) | Cantargia AB (publ) ("Cantargia" or the "Company") hereby announces that the board of directors has resolved to carry out a new share issue of approximately SEK 124 million with preferential rights... ► Artikel lesen | |
| 21.05. | Bulletin from the Annual General Meeting in Cantargia AB | 388 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 21, 2026 / Cantargia (STO:CANTA) - The Annual General Meeting of Cantargia AB (publ) on May 21, 2026 resolved in accordance with the following:To adopt the income statement... ► Artikel lesen | |
| 19.05. | Cantargia Publishes Interim Report for The First Quarter of 2026 | 442 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 19, 2026 / Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2026."The first quarter of 2026 reflects both strong... ► Artikel lesen | |
| 06.05. | Invitation to the Presentation of Cantargia's Interim Report for Q1 2026 | 349 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for Q1 2026 on Tuesday, May 19, 2026, at 07:00 a.m. CEST.In conjunction... ► Artikel lesen | |
| 27.04. | Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML | 423 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 27, 2026 / Cantargia AB (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced early... ► Artikel lesen | |
| 17.04. | Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC | 507 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (Nasdaq Stockholm:CANTA) today reported that the rationale and study design of the phase 1b/2 clinical trial... ► Artikel lesen | |
| 17.04. | Notice of Annual General Meeting in Cantargia AB | 279 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ), reg. no. 556791-6019, are invited to the annual general meeting on Thursday, 21 May 2026... ► Artikel lesen | |
| 17.04. | Cantargia Publishes Annual Report 2025 | 301 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that the annual report for 2025 has been published. The Annual Report is attached to this press... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 99,80 | -0,05 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| EVOTEC | 3,356 | 0,00 % | Evotec Aktie: Die Sorgen werden nicht kleiner | Der Erholungsversuch bei der Evotec Aktie ist verpufft und der Biotechnologie-Titel steht wieder da, wo es ungemütlich wird. Nach dem starken Wochenauftakt drehte der Wind, als die Quartalszahlen enttäuschten... ► Artikel lesen | |
| QIAGEN | 37,565 | -3,02 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| REGENERON PHARMACEUTICALS | 715,30 | +0,17 % | Dividendenbekanntmachungen (18.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ATKORE INC US0476491081 0,33 USD 0,285 EUR AVISTA CORPORATION US05379B1070 0,4925 USD 0,4253 EUR BWX TECHNOLOGIES INC US05605H1005 0... ► Artikel lesen | |
| BRAIN BIOTECH | 2,700 | -0,37 % | Brain Biotech: Sven K. Weber wird neuer Vorstandsvorsitzender | Der Aufsichtsrat der Brain Biotech AG hat Sven K. Weber zum 1. Oktober 2026 für drei Jahre zum neuen Vorstandsvorsitzenden bestellt. Der 44-Jährige war seit 2011 in verschiedenen Führungspositionen... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| CARDIOL THERAPEUTICS | 1,602 | +0,25 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CSL | 103,98 | +0,48 % | Could CSL shares really hit $200? Experts reveal their 12-month targets | ||
| BURCON NUTRASCIENCE | 1,090 | +3,81 % | Stonegate, Inc.: Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) 1Q27 | Dallas, Texas--(Newsfile Corp. - August 13, 2026) - Burcon Nutrascience Corporation (TSX: BU): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU). Burcon's... ► Artikel lesen | |
| MANNKIND | 3,645 | +2,68 % | MannKind-Aktie: Biotech-Chance mit neuen Wachstumstreibern | Die MannKind-Aktie steht nach zwei wichtigen FDA-Zulassungen vor einer neuen Wachstumsphase. Bei einer Marktkapitalisierung von rund 1,24 Milliarden US-Dollar könnte der Markt das langfristige Potenzial... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,700 | +2,11 % | Why Is Ocular Therapeutix Stock Gaining Monday? | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,937 | -0,05 % | Oxford Nanopore CEO receives 49,676 shares under LTIP award | ||
| ADAPTIMMUNE THERAPEUTICS | 0,162 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 1,428 | +7,05 % | Codexis, Inc.: Codexis Reports Second Quarter 2026 Financial Results | Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO... ► Artikel lesen | |
| CORMEDIX | 7,000 | -0,26 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen |
CANTARGIA AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,178 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.